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A B S T R A C T
Interleukin-1 beta (IL-1β) is a cytokine linking the neuroendocrine system and metabolic homeostasis. We have
previously demonstrated the relevance of IL-1β for maintaining the pituitary ACTH-producing cells by immuno-
blocking its effects in pituitary cultures. However, the morphological characteristics and the intimate re-
lationship of the pituitary cells expressing IL-1β and ACTH remain unknown. For determining pituitary varia-
tions of immunoreactivity for IL-1β and its relation with ACTH-positive cells under stress situations, we per-
formed an immunohistochemical analysis of the expression of IL-1β and ACTH in the pituitary gland of adult
rats, in the absence or presence of corticosterone, by establishing different groups: untreated, sham-operated,
and bilaterally adrenalectomized animals. In the rats subjected to surgery, the glucocorticoid was administered
on the same day of the intervention and on the third day post-surgery. Interestingly, it was observed that IL-1β
was located in the pituitary endothelial cells at the hypophyseal portal vessels, regardless of the treatment
schedule. When comparing the pituitary immunoreactive surface to IL-1β expression without corticosterone,
adrenalectomized animals displayed a significantly greater area than the sham-operated animals. Corticosterone
significantly inhibited the effect of adrenalectomy depending on the time interval it was administered. By in situ
hybridization, IL-1β mRNA expression was also correlated with immnunocytochemical expression of pituitary
IL-1β. Our results demonstrate that IL-1β is a constitutive element in endothelial portal pituitary vessels and
under stress experimental conditions IL-1β increases its expression and its relation with ACTH-positive cells,
suggesting that IL-1β could participate in an autocrine-paracrine fashion thereby modulating the pituitary po-
pulation of ACTH-positive cells.
1. Introduction
The interleukin-1 family of cytokines encompasses several poly-
peptides involved in systemic pathways related to the immune and
endocrine system, and also participates in cell growth, differentiation
and function [1]. Furthermore, the relevance of IL-1β, a cytokine re-
lated to the inflammasome, which links the regulation of inflammatory
responses and immunomodulation with the neuroendocrine system and
metabolic homeostasis, is noteworthy [2–4].
IL-1β is released by different cellular types and, as a proin-
flammatory cytokine, many of its relevant actions are implicated in the
modulation of the HPA axis [5–8].
The pituitary synthesizes both IL-1β and its receptor, as their mRNA
and protein expression have been demonstrated [9–12].
Because IL-1β and its specific receptor are present in the pituitary
gland [13] autocrine-paracrine effects have been attributed to this
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hypophyseal IL-1β, such as a regulator of hormonal secretion, together
with the differentiation, proliferation and apoptosis of several pituitary
cells [14–18].
Concerning the regulation of the HPA axis, IL-1β stimulates the
secretion of POMC derivatives thus promoting the release of ACTH
[16,19–21]. Indeed, the relationship between the hypophyseal IL-1β
and the HPA axis follows a bidirectional feedback pattern [5,6,22],
including the notorious influence regarding the time course, and cor-
relation with an autocrine-paracrine regulation at the pituitary level
[12,23]; although, some aspects concerning the cellular characteristics
or local variations still remain unknown.
The question of how this network implicates both the pituitary IL-1β
and the HPA axis, considering their bidirectional autocrine-paracrine
regulation and their participation in the maintenance of populations of
relevant cellular elements involved in these processes, has been of
particular interest in our own research [17,18,24].
Therefore, in order to answer questions regarding this and to com-
plement our previous findings, the aim of this study was to elucidate the
characteristics and variations of the pituitary cells that might show
immunoreaction to IL-1β, by analyzing groups of control, simulated or
adrenalectomized adult rats. Additionally, a possible correlation with
the pituitary immunocytochemical expression of ACTH was also studied
in these animals. Following a brief period after the administration of
corticosterone to the groups of rats submitted to their corresponding
surgical procedure, and by using double immunohistochemical labeling
for ACTH and IL-1β respectively, possible modifications in both the
pituitary ACTH-positive cells and IL-1β-positive cells were analyzed.
2. Materials and methods
2.1. Animals and experimental protocol
The experiments were carried out following the protocols and
ethical requirements approved by the Committee for the Care and Use
of Animals of the University of Salamanca, in accordance with the
regulations for the use of animals in investigation procedures from the
European Communities Council Directive (2010/63/EU) and the cur-
rent Spanish legislation (RD 53/2013).
For all the experimental procedures, adult male Sprague-Dawley
rats 8 weeks-old and weighing 175–200 g were used. The animals were
individually housed under controlled conditions, in a room maintained
at 21 ± 2 °C and 50 ± 5% of relative humidity, with a controlled
cycle of 14 h light – 10 h darkness. A balanced standard rat diet
(Panlab®, Barcelona, Spain) and water were freely available. The
groups of animals used for the experiments were as follows (Table 1):
Untreated rats. 5 phenotypically normal rats without any treatment.
Sham-operated (simulated). 40 rats of this group were submitted to
surgery although, after laparotomy, the adrenal glands were localized
but not removed, and no other surgical procedure was carried out. The
animals were sacrificed after 2, 4 or 6 days of surgery, 5 rats per time
interval, and the other 25 rats were treated with corticosterone as later
described.
Adrenalectomized rats. 40 rats were bilaterally adrenalectomized by
a dorsal extraperitoneal laparotomy under ketamine anesthesia
(10 mg/kg body weight, administered intraperitoneally); after the sur-
gical procedure, the drinking water was supplemented with 0.9% NaCl
and 5% sucrose, as previously described [25]. The animals were sa-
crificed 2, 4 or 6 days after surgery, 5 rats per time interval, and the
other 25 rats were treated with corticosterone as later described.
Rats treated with corticosterone. 50 rats, 25 sham-operated and 25
adrenalectomized, were treated with corticosterone (1.5 mg/kg body
weight b.i.d, intramuscularly/12 h). In every surgical circumstance two
groups were established. One group was treated starting from the same
day of the surgery (day 1) until the day of sacrifice, which occurred on
days 2, 4 or 6. In the second group, the treatment with corticosterone
started on the 3rd day after surgery (day 3) and animals were sacrificed
on days 4 or 6. For every time point, 5 rats were studied.
2.2. Sample processing
After the corresponding treatment period, the animals were an-
esthetized with isoflurane inhalation and were sacrificed by decapita-
tion between 10 am and 11 am. Immediately, the pituitary glands were
carefully dissected and fixed in a solution of paraformaldehyde 4% in
phosphate buffer (0.1 M, pH 7.4) for 24 h. Then, the samples were
dehydrated in ethanol, cleared in xylene, and embedded in paraffin for
making serial coronal sections with a thickness of 5 µm.
2.3. Immunohistochemistry
For single immunostaining, the streptavidin-peroxidase method was
used; in double immunostaining, the streptavidin-peroxidase method
was used followed by the peroxidase-antiperoxidase (PAP) reaction.
The slides were previously deparaffinized and rehydrated. The en-
dogenous peroxidase was blocked by incubating with 0.25% H2O2 in
methanol for 30 min. Afterwards, they were washed three times in TBS
(Trizma-HCl buffered saline 0.05 M, pH 7.4, plus 0.9% NaCl, used as
the solution for washes and dilutions). The non-specific reaction of the
secondary antibody was blocked by incubation in normal goat serum
(Dako®, Glostrup, Denmark, diluted 1:30 in TBS) for 30 min.
The single immunostaining method was performed to detect IL-1β
expressing cells: the sections were incubated in the primary antibody,
polyclonal rabbit anti-rat IL-1β (Endogen®, Endogen Inc., Woburn, MA,
USA, diluted 1:120 in TBS) for 24 h at 4 °C in a humidity chamber. After
washing, the slides were incubated for 45 min at room temperature
with a biotinylated-goat anti-rabbit IgG (Caltag®, San Francisco, CA,
USA, diluted at 1:150 in TBS) and then for 30 min at room temperature
with streptavidin-horseradish peroxidase complex (Caltag®, diluted at
1:250). Then, the sections were washed again with TBS, and the reac-
tion was revealed using a freshly prepared solution of 3,3′-diamino-
benzidine tetrahydrochloride (DAB; Sigma®, Sigma-Aldrich Inc., St.
Louis, MO, USA), at 0.025% in TB (Trizma-HCl buffer 0.05 M, pH 7.4),
plus 0.03% H2O2. The samples were counterstained with Mayer’s he-
matoxylin.
In order to confirm the specificity of the immune reaction, sub-
stitution of the primary antibody by TBS or non-immune rabbit serum,
Table 1
Scheme of the experimental protocol.
Groups of animals Corticosterone treatment
1.5 mg/kg body weight twice daily





Day 1 Day 3
Untreated 5 – – Not applied
Sham-operated 5 – – 2
5 – – 4
5 – – 6
Adrenalectomy 5 – – 2
5 – – 4
5 – – 6
Sham-operated 5 5 – 2
10 5 5 4
10 5 5 6
Adrenalectomy 5 5 – 2
10 5 5 4
10 5 5 6
a Following the surgical procedure, the glucocorticoid was administered on the same
day of surgery (Day 1) and on the third day after the intervention (Day 3) for the in-
dicated groups.
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and preabsorption tests with rat IL-1β (10 ng/ml) were carried out, and
in all cases the reaction was abolished.
A double-labeling immunocytochemical method was developed to
jointly study of IL-1β- and ACTH-positive cells. The first label applied
was for IL-1β in a similar protocol as described for the simple im-
munolabeling, and then tested for ACTH. In order to avoid cross-reac-
tion among the antibodies employed in both labels, after detection of
IL-1β-positive cells elution of IgG was carried out by incubation in
glycine buffer (0.2 M, pH 2.2) overnight at 4 °C, followed by two wa-
shes in TBS. The peroxidase-antiperoxidase (PAP) reaction was per-
formed for the detection of ACTH by overnight incubation at 4 °C with
polyclonal rabbit anti-ACTH antibody (Dako®, diluted 1:800 in TBS)
then, a swine anti-rabbit IgG (Dako®, diluted 1:100 in TBS), and the
PAP soluble complex (Dako®, diluted 1:100 in TBS) were successively
applied at room temperature for 40 and 30 min, respectively. The re-
action was finally visualized by using a freshly prepared solution of 4-
chloro-1-naphthol (1.7 × 10−3 M in 3% absolute ethanol in TB, con-
taining 0.3% H2O2). The control methods included the substitution of
the primary antibodies, preabsorption tests, as well as omission of the
secondary antibody or PAP complex; after these tests, no im-
munoreactivity was detected.
2.4. In situ hybridization
To detect mRNA expression of IL-1β in the pituitary gland, in situ
hybridization was performed by a non-isotopic method involving the
immunocytochemical detection of biotin using the streptavidin-biotin-
peroxidase method, as has been previously described [26,27]. For this
study there were used as probes the sense biotinylated oligonucleotide
5′Bio-ccacctcaatggacagaacataagccaacaagtggt, and antisense 5′Bio-
ggtggagttacctgtcttgtattcggttgttcacca, 100% specific to rat IL-1β ac-
cording to the NCBI Reference Sequence NM_031512.2.
To avoid RNase contamination in this procedure, all solutions and
equipment were treated with diethylpyrocarbonate. The sections were
previously deparaffinized and rehydrated, and after postfixation in 1%
paraformaldehyde (to avoid the appearance of false positives), they
were incubated 15 min twice in phosphate-buffered saline (PBS) and
equilibrated for 15 min in standard saline citrate (1xSSC = 150 mM
NaCl, 15 mM sodium citrate, pH 7.0). Afterwards, the slides were pre-
incubated with a hybridization buffer (Omnibufer®, WAK-Chemie
Medical GmbH, Germany) for 2 h at 55 °C using a humidity chamber.
Hybridization with the biotinylated-probe (400 ng/ml in Omnibuffer®)
was carried out by using a humidified chamber overnight at 55 °C. The
reaction was stopped by washing sequentially in high stringency con-
ditions in 2xSSC at room temperature for 30 min, in 2xSSC at 65 °C for
1 h, in 0.1x SSC at 65 °C for 1 h, and equilibrated for 5 min in Tris-
buffered saline buffer (100 mM Tris–HCl, 150 mM NaCl, pH 7.5). Biotin
was detected using monoclonal anti-biotin antibody (Roche®, Basel,
Switzerland, diluted 1:350 in TBS: 0.05 M HCl-Trizma, pH 7.4, plus
0.8% NaCl) overnight at 4 °C in a humidity chamber, followed by
biotinylated goat anti-mouse antibody (Abcam®, Cambridge, UK, di-
luted 1:150 in TBS). The final reaction was developed with DAB
(Sigma®, Sigma-Aldrich Inc., St. Louis, MO, USA) in 0.05 M TB buffer,
pH 7.4, to which 0.03% H2O2 had been added. The slides were coun-
terstained using Mayer’s acid hematoxylin. As controls, hybridization
with sense probe, omission of the probe and pretreatment with RNase
were performed, no reaction being observed in any case.
2.5. Quantification, morphometry and densitometry
By using a Labophot-2 Nikon® microscope, digital images at a final
magnification of 400× were taken from 15 fields obtained from 10
different pituitary sections, per animal studied, randomly-selected from
all parts of the gland and separated from each other by at least 100 µm.
The digital photomicrographs were acquired under homogeneous con-
ditions of color and temperature, without modifications to the voltage
during the capture process.
ImageJ 1.49 software (developed by the National Institutes of
Health, USA and freely downloaded from http://imagej.nih.gov/ij) was
used to select positive elements by densitometric identification, in order
to obtain the surface area occupied by IL-1β in the pituitary field
analyzed. This protocol was used because most often the IL-1β-positive
endothelial cells were bigger than the thickness of the sections.
Accordingly, the percentage of the pituitary surface occupied by IL-1β-
positive elements was calculated. The densitometrically identified po-
sitive-elements were grouped and, after taking a digital mask by auto-
matic segmentation, the area occupied by each element was calculated
and the percentage of the field area occupied by the corresponding
immunocytochemical reaction was calculated from a field of
47.000 µm2 of the total pituitary surface.
To determine the percentage of ACTH-positive cells, the number of
ACTH-positive cells from 4000 pituitary cells was calculated for every
animal by a double-blind method, and the total percentage of ACTH-
positive cells was calculated for every group studied. Moreover, ACTH-
positive cells contacting IL-1β-positive elements were accounted sepa-
rately of those ACTH-positive cells no-contacting with IL-1β elements.
2.6. Statistical analysis
The values obtained were analyzed statistically by using GraphPad
Prism 6 (GraphPad Software Inc., San Diego, CA, USA). The results are
shown as mean values ± SEM (standard error of the mean) in the text
and plots.
The differences between means obtained were contrasted with
double-tail ANOVA (analysis of variance), considering statistical sig-
nificance when p < 0.05 in the post hoc Scheffe’s F-test.
3. Results
3.1. Immunoreactivity for IL-1β
Adult rats showed immunoreactivity for IL-1β confined mainly but
not exclusively to the ECs of hypophyseal vascular sinusoids. The im-
munocytochemical reaction was usually more intense in the marginal
sinusoids than in those at the center, with no significant differences
between the untreated and the sham-operated rats (Fig. 1A). After bi-
lateral adrenalectomy the immunoreactivity for IL-1β increased con-
siderably in extent and intensity, affecting the marginal sinusoids on
the second (day 2) or fourth day (day 4) following surgery, while both
the central and peripheral sinusoids showed a positive reaction on the
sixth day (day 6) after the adrenalectomy (Fig. 1A).
After treatment with corticosterone the immunoreactivity for IL-1β
declined over time. Although this effect was evident in sham-operated
animals, it was more significant in the animals previously adrena-
lectomized (Fig. 1A), particularly if the adrenalectomized rats had re-
ceived corticosterone starting from the same day of surgery.
Under high-magnification, as shown in Fig. 1C, the pituitary IL-1β
positive cells were brownish and, when the untreated rats were com-
pared with adrenalectomized animals after 6 days, an intense reaction
was observed in the latter, which almost disappeared when these ani-
mals were treated with corticosterone.
Similar results as described for ECs were observed in some endo-
crine non-ACTH-positive pituitary cells (Figs. 1C and 3).
3.2. Percentage of pituitary surface occupied by immunoreactivity for IL-1β
Fig. 1B summarizes the variations found in the percentages of pi-
tuitary surface occupied by immunoreactivity for IL-1β, in ECs and
endocrine positive cells.
A small percentage of the pituitary surface (0.79 ± 0.05%) corre-
sponded to cellular elements reactive for IL-1β in the untreated animals.
Sham operated animals sacrificed two days after surgery showed a
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significant increase (p < 0.05, in relation to untreated animals) in the
immunoreactive surface. Later on, the effects of the surgery dis-
appeared and no significant variations were observed at 4 or 6 days
after surgery when compared to the untreated animals.
As can be expected, after adrenalectomy the pituitary surface oc-
cupied by immunoreactivity to IL-1β increased significantly (p < 0.01
in relation to untreated and sham-operated animals sacrificed at the
same time interval), and this increase became greater as the time period
post-surgery elapsed.
Treatment with corticosterone starting on the first day of surgery
prevented the effects of surgery in sham-operated (p < 0.05) and
adrenalectomized animals (p < 0.01). However, significantly larger
surfaces (p < 0.05) were observed for the adrenalectomized rats when
compared to sham-operated animals at the same time interval.
Fig. 1. Pituitary-positive cells to IL-1β. (A) Photomicrographs showing the brown-colored reaction of the immunopositive pituitary cells in untreated (UT), simulated (Sham), and
bilaterally adrenalectomized (ADX) animals after the 4th or 6th day of surgery, without and with the administration of corticosterone (Cort) for 1 or 3 days. Scale bar: 50 µm. (B) Plotting
showing the percentage of surface of the pituitary gland occupied by immunohistochemically-positive cells to IL-1β, in every group studied. Values represent mean ± SEM. (C) Pituitary-
positive reaction to IL-1β (brown-colored) in simulated rats (Sham), bilaterally adrenalectomized (ADX), and bilaterally adrenalectomized and treated with corticosterone from the 1st
day after surgery (ADX + Cort). Scale bar: 50 µm. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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When corticosterone was administered on day 3 after surgery, it
blocked the effects of the sham surgery and the adrenalectomy, and the
pituitary surface immunoreactive to IL-1β was significantly lower when
compared to the corresponding animals that had not received the cor-
ticosterone treatment (p < 0.05 for sham-operated animals and
p < 0.01 for adrenalectomized animals). Significant differences among
sham-operated and adrenalectomized animals were detected at day 4
and day 6 intervals (p < 0.05). The immunoreactive surface was dis-
cretely larger in animals treated with corticosterone on day 3 than those
observed in the adrenalectomized animals treated with the glucocorti-
coid starting from the first day of surgery (p < 0.05). The animals
were sacrificed on day 4 after the adrenalectomy.
3.3. ACTH-positive cells and immunoreactivity for IL-1β
As expected, surgical stress on the sham-operated and the adrena-
lectomized animals significantly increased the percentage of pituitary
ACTH-positive cells (Fig. 2A, blue cells, and B). However, surgical stress
only increased this percentage on days 2 and 4 post-surgery (p < 0.01
in relation to untreated animals), while the percentage of ACTH-posi-
tive cells increased significantly (p < 0.01 in relation to sham animals,
and p < 0.005 in relation to untreated animals) and linearly from day
2 to day 6 (Fig. 2B). Significant differences (p < 0.01) were observed
between day 2 and day 4, or from day 4 to day 6. Treatment with
corticosterone blocked or reverted these changes (p < 0.05 in sham-
operated animals and p < 0.005 in adrenalectomized animals).
ACTH-positive cells (blue cells in Figs. 2 and 3) were irregular or
stellate cells with cytoplasmic prolongations. Double immunolabeling
revealed that two different populations of ACTH-positive cells could be
considered: ACTH-contacting IL-1β and ACTH-non contacting IL-1β
(Figs. 2A and 3A). The results observed when the percentage of ACTH-
contacting IL-1β, from the total percentage of ACTH-positive cells
analyzed, are summarized in Fig. 3B. On day 2 (p < 0.05) and day 4
(p < 0.01) post-surgery, the percentage of ACTH-contacting IL-1β in-
creased significantly in sham-operated animals in comparison to the
untreated animals. This result was not observed for day 6. After adre-
nalectomy a marked increase in the percentage of cells was observed
(p < 0.001 in relation with untreated animals). When sham-operated
and adrenalectomized animals were compared, the adrenalectomy in-
creased the percentage of ACTH-contacting IL-1β on day 2
(p < 0.005), day 4 (p < 0.005) and day 6 (p < 0.001).
Corticosterone decreased linearly from day 2 to day 6 in all of the
groups treated within the study (p < 0.05 in sham-operated animals
and p < 0.001 in adrenalectomized animals).
Fig. 2. Pituitary-positive cells to ACTH. (A) Morphology
and immunoreaction of ACTH-positive cells (blue-colored,
some indicated with arrows), and its relation with positive
immunoreaction to IL-1β (brown-colored), in simulated
(Sham) and bilaterally adrenalectomized (ADX) rats, at 2, 4
or 6 days after surgery, and the effects of corticosterone
(+Cort) administration at day 1 or after 3 days of the cor-
responding surgical procedure. Scale bar: 50 µm. (B) Effects
of corticosterone administration on simulated (Sham) or
adrenalectomized (ADX) animals, related to the percentage
of ACTH-positive cells. Values represent mean ± SEM. (For
interpretation of the references to colour in this figure le-
gend, the reader is referred to the web version of this ar-
ticle.)
M.C. Iglesias-Osma et al. Cytokine 99 (2017) 9–17
13
3.4. In situ hybridization for pituitary IL-1β mRNA in the pituitary gland
In situ hybridization showed that pituitary IL-1β mRNA was weakly
expressed in untreated rats (Fig. 4A). Surgical stress in both the sham-
operated animals (Fig. 4B) and those adrenalectomized (Fig. 4C)
markedly increased the pituitary expression of IL-1β mRNA, as was
found by immunocytochemistry. In situ hybridization was more sensi-
tive than immunocytochemistry to detect pituitary IL-1β in ECs and
endocrine cells. Positivity for IL-1β mRNA was observed in endocrine
and endothelial cells, these latest mainly in adrenalectomized animals
(Fig. 4C, arrow). Endothelial expression of pituitary IL-1β mRNA in
adrenalectomized rats treated with corticosterone (Fig. 4D) showed
similar changes as those described above for the endothelial im-
munocytochemical reaction to the pituitary IL-1β protein.
4. Discussion
The cellular expression of IL-1β has been mainly attributed to cells
of the monocyte-macrophage system, although it has been reported that
diverse conditions may also induce the protein and mRNA expression of
this cytokine in vascular ECs in different sites and among diverse
mammalian species [28–33]. The results of the present study show a
constitutive expression of the IL-1β in ECs of the adult rat pituitary
gland and to our knowledge this is the first report providing evidence
regarding the immunohistochemical expression of IL-1β protein and its
mRNA in some of the rat pituitary ECs and endocrine cells.
As it is well known, the pituitary is vascularized mainly by portal
vessels that act as capillary sinusoids with fenestrated endothelium that
facilitates a bidirectional permeability for molecules of different char-
acteristics [34]. Despite the original publication regarding hypophyseal
immunoreactivity for IL-1β [9], and evidence supporting the expression
of IL-1 receptor type 1 (IL-1R1) mRNA within the pituitary [11], a
possible peripheral origin for this cytokine was proposed [35].
Regardless of this controversy, it was later reported that in adre-
nalectomized mice the administration of lipopolysaccharide (LPS) en-
hanced the expression of IL-1β within the pituitary at both the protein
and mRNA level [22]. Additionally, the pituitary production of the IL-
1β converting enzyme (ICE) and the constitutive and inducible forms of
the cytokine were also identified [36]. This evidence supported the idea
of the in situ production of functionally active IL-1β in the pituitary.
Furthermore, stress induces IL-1β in the brain which is inhibited by
corticosterone administration [37]. Remarkably, in certain situations,
IL-1β mRNA expression in rodent brain followed a time-course pattern,
principally at the glial level; while the capillary endothelium has also
been suggested as another possible source of IL-1β in the brain
[12,23,38,39].
Interestingly, it was described that the peripheral administration of
LPS in rats induces de novo synthesis of bioactive IL-1β in the ECs of
their CVO [40], whose endothelium is arranged in a fenestrated layer
like the portal pituitary sinusoids. In addition, the presence of IL-1R1
protein and mRNA in rat brain vascular cells was also demonstrated by
the same authors [41].
In streptozotocin-diabetic rats, a stressor condition as is hypergly-
cemia induces the expression of IL-1β from the isolated retinal vascular
endothelium, and the cytokine is also stimulated in an autocrine and
paracrine fashion resulting in an increased synthesis of IL-1β, both in
the glial and endothelial cells [32].
Indeed, it has been demonstrated that the response of the HPA-axis
and the release of ACTH and corticosterone, elicited by exogenous
administration of IL-1β in mice, are mediated by brain ECs expressing
Fig. 3. Pituitary ACTH-positive cells contacting IL-1β-posi-
tive cells in untreated, simulated (Sham) and bilaterally
adrenalectomized (ADX) rats, with or without corticos-
terone (+Cort) treatment. (A) High magnification photo-
micrographs showing the population of ACTH-positive cells
(blue-colored) contacting IL-1β (arrows). Scale bar: 50 µm.
(B) Percentage of ACTH-positive cells contacting IL-1β from
the total percentage of ACTH-positive cells, for all the
groups of animals studied; the glucocorticoid was adminis-
tered at day 1 or after 3 days of the surgical intervention.
Values represent mean ± SEM. (For interpretation of the
references to colour in this figure legend, the reader is re-
ferred to the web version of this article.)
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the IL-1β receptor [42]. Thus, taking into account the support of the
aforementioned evidence (expression of both IL-1β and its receptor IL-
1R1 in the brain ECs of rodent), together with the recognized autocrine-
paracrine actions of IL-1β in the HPA axis, the expression of IL-1β at the
pituitary vascular cells might well be possible.
In our study, an increased expression of IL-1β in the pituitary en-
dothelium was observed in the groups of rats subjected to surgical in-
tervention without any other type of procedure, indicating an activa-
tion of the HPA axis related to the surgical stress. Furthermore, the
adrenalectomized rats showed a maximal expression of the cytokine,
both morphologically and in the percentage of area, that was directly
proportional to the number of days post-surgery. Our findings of in-
creased IL-1β expression in the vascular pituitary sinusoids of rat sug-
gest that some of the hypophyseal endothelial cells are also a source of
IL-1β, and that IL-1β expression is highly related to stress and the HPA
axis.
In the analysis of human umbilical vein and human aortic ECs, after
administering physiological doses of cortisol or dexamethasone, it has
been reported changes in the morphology of ECs and the inhibition of
some functional aspects associated to their relationships with the
neighboring cellular elements [43]. Likewise, in our study the admin-
istration of corticosterone in simulated or adrenalectomized animals,
following a time-course, significantly reduced both the IL-1β morpho-
logical expression and percentage of the immunoreactivity area of some
of the pituitary ECs. Hence, this suggests that the inhibitory actions of
the glucocorticoid on the release of IL-1β also occur within the pituitary
endothelium.
The need for using classical markers to identify ECs could be pro-
posed. However, this is unnecessary considering that the absence of
these indicators is a particularity of the sinusoidal ECs of the pituitary
portal vessels [44].
The morphometry and the densitometric assessment used the NIH
ImageJ software, a computer-assisted image analysis widely accepted,
provides objectivity, accuracy, reproducibility, and time efficiency
compared to manual cell counts [45,46].
The pituitary vascular sinusoids exhibited an irregular shape, with
ECs of irregular shape and spatial disarrangement, and as a con-
sequence were located in the same plane of section. As a result, we
found nucleated and non-nucleated IL-1β-positive cellular fragments
that made it impossible to distinguish if they were from the same or
different cells. Therefore, we chose to calculate the pituitary surface
occupied by IL-1β rather than calculate the percentage of ECs cells.
IL-1β mRNA expression was observed in endocrine and endothelial
cells. Certainly, determining the mRNA expression of IL-1β in the pi-
tuitary endothelium has been of particular interest, especially con-
sidering that it has been reported its presence in other vascular en-
dothelial cells [28,31]. Indeed, in the present work we have also
demonstrated by in situ hybridization that endothelial expression of
pituitary IL-1β mRNA goes in parallel and is in accordance with the
variations detected in this study by immunocytochemistry for the en-
dothelial expression of pituitary IL-1β protein.
The results obtained in the present study after analyzing the per-
centage of ACTH-positive cells are in agreement with the findings ob-
served in previous studies from our laboratory where effects of
Fig. 4. Photomicrographs showing IL-1β mRNA-positive pituitary cells
detected by in situ hybridization (being developed with DAB and coun-
terstained with hematoxylin). (A) Untreated rats. (B) Sham-operated ani-
mals at 4 days after surgery, (C) Bilaterally adrenalectomized (ADX) rats
after the 4th day of surgery, without the administration of corticosterone
(Cort), where an IL-1β mRNA-positive endothelial cell is indicated (arrow),
and (D) Bilaterally adrenalectomized (ADX) animals after the 4th day of
surgery, with the administration of corticosterone (Cort) for 1 day. Scale
bars: (A) 25 µm; (B, C and D): 10 µm.
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adrenalectomy with or without treatment with corticosterone on cel-
lular proliferation and apoptosis were studied [24].
5. Conclusions
As demonstrated by our results, we were unable to find, in all
groups of the rats studied, a co-localization of the immunostaining for
ACTH or IL-1β. We only observed relationships among the cells that
were immunopositive for the cytokine or the hormone within the same
regions. The changes observed by surgical stress, adrenalectomy or
treatment with corticosterone demonstrated that the variations of
ACTH-positive cells are associated to similar variations of the pituitary
surface occupied by IL-1β, and variations in the contact among ACTH-
and IL-1β-positive cells. This suggests an important relationship be-
tween increases of endothelial pituitary IL-1β and the pituitary re-
sponses of the HPA to stress. Therefore, this might involve a pituitary
release of IL-1β under stress and/or a paracrine regulation of ACTH by
IL-1β. Moreover, as was reported using similar experimental conditions
[28,32], endothelial pituitary IL-1β could exert an autocrine effect on
ECs.
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